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Abstract Growth hormone (GH) can profoundly influence
cardiac function. While GH excess causes well-defined
cardiac pathology, fewer data are available regarding the
more subtle cardiac changes seen in GH deficiency (GHD).
This preliminary study uses cardiac magnetic resonance
imaging (CMR) to assess myocardial structure and function
in GHD. Ten adult-onset GHD patients underwent CMR,
before and after 6 and 12 months of GH replacement. They
were compared to 10 age-matched healthy controls and sex-
matched healthy controls. Left ventricular (LV) mass index
(LVMi) increased with 1 year of GH replacement (53.8 vs.
57.0 vs. 57.3 g/m2, analysis of variance p= 0.0229). Com-
pared to controls, patients showed a trend towards reduced
LVMi at baseline (51.4 vs. 60.0 g/m2, p= 0.0615); this
difference was lost by 1 year of GH treatment (57.3 vs. 59.9
g/m2, p= 0.666). Significantly reduced aortic area was
observed in GHD (13.2 vs. 19.0 cm2/m2, p= 0.001). This
did not change with GH treatment. There were no differ-
ences in other LV parameters including end-diastolic
volume index (EDVi), end-systolic volume index, stroke
volume index (SVi), cardiac index and ejection fraction.
There was a trend towards reduced baseline right ventricular
(RV)SVi (44.1 vs. 49.1 ml/m2, p= 0.0793) and increased
RVEDVi over 1 year (70.3 vs. 74.3 vs. 73.8 ml/m2, p=
0.062). Two patients demonstrated interstitial expansion,
for example with fibrosis, and three myocardial ischaemia
as assessed by late gadolinium enhancement and stress
perfusion. The increased sensitivity of CMR to subtle car-
diac changes demonstrates that adult-onset GHD patients
have reduced aortic area and LVMi increases after 1 year of
GH treatment. These early data should be studied in larger
studies in the future.
Introduction
Growth hormone deficiency (GHD) causes myocardial
hypokinesis, with loss of the normal response to exercise
[1–5]. Effects of GHD on cardiac mass have been most
clearly demonstrated in childhood-onset GHD (CO-GHD)
but the impact of adult-onset GHD (AO-GHD) remains
controversial, with variable conclusions in different studies
[6–10]. The difficulties defining the effect of AO-GHD on
cardiac mass are due, in part, to limitations in traditional
methods of assessment [11, 12]. GH replacement improves
exercise tolerance, but it is unclear if this is due to changes
in cardiac mass, function or circulating volume [3]. Indeed,
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there are several ways in which GH is thought to act on the
heart with GH excess leading to a specific cardiomyopathy
characterised by concentric ventricular hypertrophy and
biventricular involvement [13]. If GH excess is left
untreated, cardiac failure develops [1]. The aetiology of this
change is thought to include both direct and indirect GH
action, via the effect of insulin-like growth factor-1 (IGF-1)
produced by the action of GH on the GH receptor. IGF-1
excess causes increased synthesis of myosin light chain-2
and troponin I, leading to cardiac cell growth [14]. IGF-1 is
also known to increase intracellular calcium and increase
calcium sensitivity of the cardiac myocytes leading to
increased cardiac contractility [15]. The administration of
recombinant IGF-1 in healthy subjects increases cardiac
performance, thought to be due to direct cardiac action as
well as a vasodilatory effect of IGF-1 via endothelial nitric
oxide synthase (eNOS) [16]. Furthermore, GH has effects on
salt and water handling via the kidney and GH excess
increases circulating volume [17]. It is clear that the GH/IGF-
1 system interacts with the cardiovascular system in multiple
ways and the cardiac pathology seen in patients with GH
excess and deficiency will arise due to a range of interactions.
Cardiac magnetic resonance (CMR) imaging is a reliable
and reproducible technique for measuring myocardial
volume, mass and function. The use of gadolinium contrast
enables assessment of myocardial perfusion, scarring and
focal fibrosis [18]. CMR has been used to study a range of
cardiomyopathies, including hypertrophic cardiomyopathy,
Marfan and Turner syndromes [19–21]. Currently, there is
only one other CMR study assessing the impact of GH
deficiency on the heart and this study confined itself to
reporting the effects on the left ventricle (LV) [22]. The
effects of GH deficiency on the right ventricle (RV) and aortic
area (AA) have not previously been studied in these patients
using CMR. Our study has sought to examine the LV, RV
and AA in this patient group, to look for evidence of inter-
stitial expansion, for example, with myocardial fibrosis as
demonstrated by late gadolinium enhancement (LGE) and to
use stress CMR and perfusion techniques to explore the
presence of ischaemic heart disease, often suggested as a
confounder in the assessment of GH-related cardiac disease.
Subjects and Methods
Patients
Ten adult patients with GHD about to commence GH
replacement were recruited from two UK endocrine centres
and were studied in the main study centre. GHD was con-
firmed by insulin tolerance or glucagon testing (peak GH<
3.0 µg/l). Cardiac function and morphology were assessed
using CMR before initiation of the chosen therapy (CMR1)
and at 6 (CMR2) and 12 months (CMR3) after treatment.
Patients provided quality of life (QoL) data using the Adult
Growth Hormone Deficiency Assessment, a disease-specific
questionnaire, weight, height and blood pressure measure-
ments and serum IGF-1 levels at each time point. Patients
with known ischaemic heart disease or hypertension before
the study were excluded. Multi-centre ethical approval was
given by the local Research Ethics Committee (06/Q0401/
53). This was an observational study and referring physi-
cians determined patient treatment according to the local
guidelines. All patients signed a consent form following
verbal and written explanation of the study.
GHD group
Ten patients (two female) participated. Two patients did not
attend CMR3, one due to discontinuation of GH replace-
ment (patient 9) and one for personal reasons (patient 7).
The mean age was 55 years (SD± 13.4), mean duration of
GHD was 6.1 years (SD± 5). Six patients had previously
undergone treatment for pituitary tumours, one had previous
hypophysitis and two had undergone radiotherapy for
meningioma. All patients had at least one other pituitary
hormone deficiency; these were appropriately replaced at
stable doses for at least four weeks before CMR1. GH
therapy was commenced at a low dose and titrated, aiming
for an IGF-1 between the median and upper limit of the age-
and sex-adjusted reference ranges [23]. For patient char-
acteristics see Table 1.
Control group
Ten individually age-matched controls and sex-matched
controls were recruited. Controls underwent one non-
contrast CMR study and provided serum for IGF-1 levels.
Controls did not receive adenosine during CMR. For their
characteristics see Table 2.
Cardiac magnetic resonance
CMR was performed at an experienced centre using a
Philips Achieva CV 1.5 Tesla magnetic resonance imaging
(MRI) scanner (Philips Medical Systems, Guildford, UK).
Standard protocols were used to generate cine images.
These were analysed using dedicated software (cmr42-Cir-
cle Cardiovascular Imaging Incorporated, Canada) to cal-
culate the following cardiac parameters: LV-end diastolic
volume (EDV), end systolic volume (ESV), ejection frac-
tion (EF), stroke volume (SV), cardiac output, LV mass
(M); RV-EDV, ESV, EF, SV. All except for EF were
indexed (normalised) to body surface area (BSA) using the
Mostellar formula and suffixed “i” [24]. CMR images were
analysed by a single observer, blinded to the underlying
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Table 1 Characteristics of patients with GHD
Pt Age Sex Symptom
duration
(years)
Reason for GHD Other medical
conditions
Medications Visits
1 73 Male 3 NFPA, TSS 2005,
EBRT 2005
Mild OSA Levothyroxine All
— — — — — Testosterone —
— — — — — Aspirin —
— — — — — Hydrocortisone —
2 49 Male 18 Prolactinoma,
medical therapy
Type 2 DM
hypertension
Ramipril All
— — — — — Candesartan —
— — — — — Levothyroxine —
— — — — — Aspirin —
— — — — — Bromocriptine —
— — — — — Metformin —
3 56 Male 10 NFPA, TSS 1998,
EBRT 1998
Levothyroxine All
— — — — — Hydrocortisone —
— — — — — Testosterone —
— — — — — Aspirin —
— — — — — Lansoprazole —
4 51 Male 3 NFPA, TSS 2006 Hypothyroidism Levothyroxine All
— — — — High cholesterol Testosterone —
— — — — — Simvastatin —
5 50 Female 4 NFPA, craniotomy
1991, EBRT 1991,
TSS 1992, TSS 2005,
EBRT 2008
Renal stones HRT All
6 58 Male 2 NFPA, TSS 2003 High cholesterol Levothyroxine All
— — — — — Hydrocortisone —
— — — — — Testosterone —
— — — — — Atorvastatin —
7 34 Female 6 Hypophysitis during
pregnancy 2003
Depression Levothyroxine 1, 2
— — — — — Seroxat —
8 76 Male 3 NFPA, pituitary
apoplexy 2007
— Levothyroxine All
— — — — — Hydrocortisone —
— — — — — Testosterone —
9 57 Male 9 Meningioma, EBRT
2000
Disordered sleep Levothyroxine 1, 2
— — — — — Carbamazepine —
— — — — — Amitripyline —
10 37 Male 3 Meningioma,
Surgery,
Radiotherapy 2006
Acute lymphoblastic
leukaemia-
chemotherapy and
cranial irradiation 1977
Levothyroxine All
— — — — — Hydrocortisone —
— — — — — Testosterone —
Pt patient identification number, Symptom duration number of years experiencing symptoms of GHD, NFPA non-functioning pituitary adenoma,
TSS transsphenoidal surgery, EBRT external beam radiotherapy, OSA obstructive sleep apnoea, HRT hormone replacement therapy with
oestrogens, visits number of CMR visits attended
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diagnosis. To assess for bias and error in the measurement
of LV mass and to ensure reliability, inter-observer varia-
bility was investigated by the independent analysis of 50 %
of scans by an experienced colleague, blinded to the ori-
ginal measurements. There were no significant differences
between these two sets of results on Bland–Altman analysis.
Stress perfusion imaging
The GHD group underwent first pass perfusion imaging
with a bolus of gadolinium contrast agent (0.05 mmol/kg),
during an intravenous infusion of adenosine (140 µg/kg/
min, given for 3 min). Three short axis slices were acquired
per cardiac cycle using a steady-state prospectively gated
turbo field echo sequence. Late gadolinium images were
acquired at least 10 min following the injection of a further
0.15 mmol/kg of contrast agent, using an inversion recovery
sequence. Perfusion and late gadolinium images were
qualitatively assessed by an experienced cardiologist blin-
ded to the underlying diagnosis.
Aortic area
Aortic dimensions were obtained from MRI scout images.
Internal distances in lateral and anterior–posterior planes
were measured at the level of the pulmonary bifurcation.
Area was calculated and indexed to BSA.
IGF-1 measurements
IGF-1 levels were measured using a chemiluminescent
immunoassay (Siemens, Surrey, UK), reporting IGF-1
levels between 25–1600 ng/ml. Age-adjusted reference
and sex-adjusted reference ranges were used. IGF-1 stan-
dard deviation scores (SDS) were calculated using a stan-
dardised reference table from the assay manufacturer.
Quality of life questionnaires
The QoL assessment of GH deficiency in adults (AGHDA)
was used for patients with GHD, in which a lower result
indicates a better QoL [25].
Adverse outcomes
There were no significant adverse outcomes from this
study. The only reported side effects were discomfort
during venous cannulation and an uncomfortable
sensation when receiving either the adenosine or the
gadolinium contrast infusion. Effects from both were
classed as mild.
Statistics
Patients in whom new diagnoses of a non-GH related
cardiac or aortic pathology were made during the study
had their results excluded from the cardiac indices or aortic
calculations, respectively. Details of any results excluded
are given in the discussion. The Student’s t-test was used
to compare patients with controls. Repeated measures
analysis of variance (ANOVA) were used to compare
repeated CMR studies. Paired t-tests were used to compare
IGF-1 SDS and QoL scores at the beginning and end of the
study. Pearson’s correlation test was used to compare IGF-
1 SDS and left ventricular mass index (LVMi). Data are
reported as mean and standard deviation, except where
specified. Analysis was performed using StatsDirect (Ian
Buchan, Cambridge, UK) and Prism (GraphPad, Cali-
fornia, USA). A p value of <0.05 was deemed to be sta-
tistically significant.
Results
Baseline anthropometric comparison of patients and
controls
Male GHD patients were heavier than their controls (p=
0.007) and had a greater body mass index (p= 0.004;
Table 2). There were no other significant differences
between the patients and their respective control groups.
Table 2 Comparison of GHD patients and their controls
Controls, n= 10 Patients, n= 10 p value
Gender (male/female) 8/2 8/2 NA
Age (years) 54 (12.1) 55 (13.4) 0.890
Male weight (kg) 71.2 (9.5) 87.8 (11.6) 0.007
Female weight (kg) 58.8 (8.1) 75.0 (19.8) 0.395
Male height (cm) 175.9 (4.6) 173.8 (9.6) 0.580
Female height (cm) 166.5 (4.9) 156.5 (2.1) 0.120
Male body mass index
(kg/m2)
23.1 (3.5) 29.1 (3.5) 0.004
Female body mass
index (kg/m2)
21.3 (4.2) 30.5 (7.3) 0.260
Systolic blood pressure
(mmHg)
133 (14) 135 (19) 0.863
Diastolic blood
pressure (mmHg)
82 (10) 83 (12) 0.811
Known hypertension
(number)
0 1 NA
Known diabetes
(number)
0 1 NA
Smoker yes/no/ex
(number)
3/5/2 2/6/2 NA
Data are given as mean (SD)
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Baseline LV characteristics
GHD patients demonstrated a strong trend towards reduced
LVMi (51.4 ± 3.2 vs. 60.0± 2.8 g/m2, p= 0.0615; Fig. 1).
No other differences in LV indices were seen: end-diastolic
volume index (EDVi) 69.5± 2.7 vs. 74.5± 2.6 ml/m2, p=
0.194; ESVi 26.6± 1.6 vs. 26.4± 2.1 ml/m2, p= 0.9288;
stroke volume index (SVi) 44.5± 1.2 vs. 46.9± 1.9 ml/m2,
p= 0.305; cardiac index (CI) 2.96± 0.2 vs. 3.33± 0.2 ml/
min/m2, p= 0.218; EF 64.6± 2.2 vs. 62.9± 0.9 %, p=
0.497. The control group had mean LVMi within the nor-
mal range [26].
LV changes at 1 year
Eight patients with GHD attended all three scans, of
which one needed to be excluded (supplementary Table 1).
In these seven patients, LVMi increased after 1 year of
treatment (53.8 ± 9.5 vs. 57.0± 11.8 vs. 57.3± 12.1 g/m2,
ANOVA p= 0.0229; Fig. 2). There were no changes
in other parameters. The trend towards a reduced LVMi
in GHD patients compared to controls at the beginning
of the study, was lost at 1 year (57.3 vs. 59.9 g/m2,
p= 0.666).
Aortic area
Patients with GHD demonstrated reduced AAi compared to
controls (13.2 ± 0.8 vs. 19.0± 1.2 cm2/m2, p= 0.001).
There was no change in AAi with 1 year of GH therapy
(p= 0.384; Fig. 3).
Baseline RV characteristics
GHD patients showed a trend towards reduced SVi
(44.1 ± 1.5 vs. 49.1± 2.2 ml/m2, p= 0.079; Fig. 4). There
were no differences in other parameters: EDVi 71.7± 4.4
vs. 78.6± 4.3 ml/m2, p= 0.275; ESVi 27.5± 3.6 vs. 29.7±
2.6 ml/m2, p= 0.629; EF 62.8± 2.6 vs. 63.0± 1.9 %,
p= 0.946.
RV changes at 1 year
Patients with GHD showed a trend towards increased RV-
EDVi with GH replacement (CMR1 vs. CMR2 vs. CMR3:
Fig. 1 Baseline LV indices in GHD patients compared to controls.
There is a strong trend towards reduced LVMi in GHD patients
(p= 0.062). Data are presented as means, error bars represent SEM
Fig. 2 LVMi of GHD patients at baseline (CMR1), at 6 months of
treatment (CMR2) and at 12 months of treatment (CMR3). There was
an increase in LVMi with treatment compared to baseline (p= 0.0229)
Fig. 3 BSA-indexed ascending aorta area in patients with GHD.
Patients have significantly lower aortic area than controls. There is no
change in aortic area with 1 year of GH therapy. Line shows mean
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70.3± 3.4 vs. 74.3± 3.1 vs. 73.8± 2.7 ml/m2, p= 0.062)
but no increase in SVi (45.8 ± 1.1 vs. 46.9± 1.8 vs. 48.6±
1.27 ml/m2, p= 0.283). There were no differences in other
parameters.
IGF-1 changes with treatment
Patients with GHD demonstrated a significant increase in
IGF-1 SDS with 1 year of GH treatment (p= 0.0032):
baseline mean IGF-1 SDS − 1.60; 1 year + 0.61. Patient 3
was over-replaced (IGF-1 SDS 3.02) so the GH dose was
reduced. Mean GH dose was 0.33 mg/day in males and
0.50 mg/day in females (Table 3).
Late gadolinium enhancement
Two patients with GHD (Patients 1 and 3) demonstrated
LGE. Patient 1 had extensive, transmural LGE, measuring
20.1 cm3. This matched an area of mildly reduced perfusion
but was not associated with a wall motion abnor-
mality. Patient 3 had mild, patchy, basal and mid-
inferolateral LGE.
Perfusion CMR
Three patients (patients 1, 3 and 8) with GHD had evidence
of stress-induced myocardial perfusion defects. Patient 1
and 8 had mild abnormalities but were symptom-free, thus
no further investigations were performed. Patient 3
demonstrated more marked perfusion abnormalities and
underwent computed tomography (CT) angiography and
clinical review by a cardiologist. This patient demonstrated
a non-flow-limiting lesion on CT angiography.
Quality of life
Patients with GHD demonstrated a significant improvement
in AGHDA score with 1 year of GH treatment (baseline
median AGHDA 17 vs. 1 year median AGHDA 5.5, p=
0.0025).
Exclusions
Patients in whom a new, non-GH-related, cardiac diagnosis
was made were excluded from relevant analyses: patient 9
had a bicuspid aortic valve and was excluded from AA
analysis; patient 2 was discovered to have hypertension and
diabetes and, therefore, was excluded from the cardiac mass
and indices analysis. With patient 2 included within the
calculations (Supplementary Table 1), LVMi in GHD
patients is similar to controls (53.9 ± 12.0 vs. 59.5± 8.0 g/
m2, p= 0.232). There is, however, a significant increase in
LVMi in GHD patients after 6 months of treatment (53.9 ±
12.0 vs. 56.6± 12.5 g/m2, p= 0.0479), as well as 12 months
of treatment when compared to their initial LVMi (56.6 ±
11.8 vs. 59.5± 12.8 g/m2, p= 0.0383). The other LV
parameter calculations remained similar when compared to
baseline.
Discussion
The cardiac complications of GHD remain poorly under-
stood [1, 15]. GHD affects many physiological systems and
is associated with a range of risk factors that may increase
the risk of ischaemic cardiac disease. CMR is established as
the most accurate method for the assessment of cardiac
mass and provides a wealth of further information on
function, ischaemia and localised fibrosis, which would
Fig. 4 Baseline RV volume indices in patients with GHD. Patients
with GHD show a trend towards reduced SVi (p= 0.0793). Data are
presented as means, error bars represent SEM
Table 3 Treatment of patients with GHD
Pt Sex Final GH dose
(mg/day)
Initial IGF1
SDS
Final IGF1
SDS
1 Male 0.30 −1.70 0.40
2 Male 0.30 −1.47 0.06
3 Male 0.50 −2.23 3.02
4 Male 0.35 −0.46 −0.01
5 Female 0.60 −3.58 −1.83
6 Male 0.20 −0.43 0.86
7 Female 0.40 −2.19 −1.46
8 Male 0.50 −2.39 −0.27
9 Male 0.20 0.41 1.44
10 Male 0.30 −1.97 1.88
Where patients dropped out before the end of the study, IGF1 level at
visit 2 is given. IGF1 given as SDS
Pt patient identification number
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previously have required additional or invasive testing [27,
28]. Patients with GHD demonstrated a strong trend
towards reduced LVMi. LVMi increased with 1 year of GH
replacement. Abnormalities during stress CMR were seen in
three patients and abnormalities on LGE imaging were seen
in two patients.
Recruitment of treatment-naive patients with AO-GHD
was particularly difficult. Since it has been shown that
replacing GH in adults with GHD is beneficial, most
patients fulfilling replacement criteria have commenced
treatment, reducing patient availability for studies [29, 30].
Some patients with very low-baseline IGF-1 experienced
significant clinical benefit from the treatment (as assessed
by AGHDA scores) although IGF-1 did not reach the nor-
mal range. Furthermore, it should be noted that although all
the patients met the criteria for severe GHD as per NICE
(National Institute of Health and Clinical Excellence)
guidelines, some patients did not have IGF-1 levels more
than 2 standard deviations beneath the median, demon-
strating the variability of IGF-1 production at different
serum GH levels. It is unclear if this influenced some
findings. However, despite small numbers of patients in this
preliminary study, we were able to demonstrate a strong
trend towards reduced LVMi in AO-GHD patients.
To date, it is well established that untreated CO-GHD
reduces cardiac mass but whether this occurs in AO-GHD
has not been clearly demonstrated [11]. Some echo studies
in patients with GHD show increased LV mass with 1 year
of GH replacement while other studies demonstrate no
change [6–10]. However, these historical studies mainly
describe patients receiving supraphysiological GH doses far
in excess of current UK guidelines (as was past practice)
and contain a mixture of both AO- and CO-GHD patients,
which may confound results. Despite using lower GH doses
than many older studies, we were able to show that GHD
patients demonstrate a significant increase in LVMi with 1
year of GH treatment. Andreasson’s CMR study of 16 AO-
GHD patients receiving similar doses of GH to this study
showed a strong trend towards increased LV mass over 1
year (p= 0.059), validating this finding [22]. The improved
accuracy of CMR over previous methods of measuring
cardiac mass has been able to show that untreated AO-GHD
is likely to be associated with reduced cardiac mass,
although larger numbers would be needed to fully demon-
strate this, and that GH replacement increases cardiac mass
in GHD.
The mechanism behind reduced cardiac mass in GHD is
likely to be multi-factorial. Withdrawal of GH replacement
in teenagers with GHD reduces skeletal muscle fibre dia-
meter [31]; whereas, high-dose GH replacement in patients
with AO-GHD increases the area of both type I and type II
skeletal muscle fibres [32]. In animal models of GHD,
cardiomyocyte area is reduced and increases with GH
therapy [33]. These findings suggest that the reduced LVMi
seen in this study is due to reduced cardiac muscle fibre
diameter, which increases with GH replacement.
Age may be an influential factor in the effects of GHD on
LV mass. The mean age of patients in this study was 55
years (range 34–76). A study of older patients with GHD
demonstrated no difference in LV mass compared to con-
trols [34]; however, a study of younger patients showed
reduced LV mass, although this contained both AO-GHD
patients and CO-GHD patients [6]. Furthermore, GH
replacement has been shown to increase LV mass in
younger patients, when similar findings were not found in a
study of older patients, although different surrogates of
mass were measured [6, 10]. It is likely that achievement of
peak cardiac mass remains under the influence of GH in
young adulthood but that in older individuals, factors other
than GH, such as blood pressure, have a more significant
effect of cardiac mass than the effect of GHD.
Right ventricular findings
CMR is considered the most accurate and reproducible
method for assessing RV volume parameters [35–37].
Patients with GHD demonstrated reduced RV SVi. There
are no published works examining RV volume parameters
by CMR in patients with GHD. However, as GH excess is
known to produce biventricular cardiac involvement, it
seems reasonable that lack of GH would also produce the
biventricular changes seen here [1, 15, 38].
One year of GH replacement in GHD did not result in
significant changes in the RV parameters that were mea-
sured, except a trend towards increasing RV-EDVi. How-
ever, as RV measurements pose technical challenges and
are more prone to error than those on the LV; larger studies
may be required to ascertain if GH replacement increases
RV cardiac indices [36].
Late gadolinium enhancement
LGE utilises the gadolinium washout characteristics of
collagen. Areas of fibrosis contain increased collagen and
retain gadolinium-based contrast longer than non-affected
areas [39, 40]. Cardiac fibrosis is not a reported feature of
GHD. Of the two patients with GHD who demonstrated
LGE, one had a missed previous myocardial infarct and one
had mild, patchy fibrosis and a myocardial perfusion defect.
Ischaemic heart disease was the probable cause of LGE in
these two patients.
Perfusion CMR
Cardiovascular mortality appears to be increased in hypo-
pituitary patients taking glucocorticoids, sex-steroids and
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thyroxine replacement, and GH treatment may improve it to
background rates [41–43]. This is thought to be due in part
to an increase in risk factors for cardiac ischaemia, such as
raised total cholesterol, low-density lipoprotein-cholesterol
and apolipoprotein B in GHD [44, 45]. In our study, one
patient with GHD had reversible ischaemia and one a pre-
vious myocardial infarction on LGE. CMR may be useful
when assessing patients with GHD, providing information
about underlying cardiovascular disease as well as identi-
fying other cardiac problems, although at present there does
not seem to be a role for such imaging in the routine care of
the GHD patient. Given the potential for ischaemic heart
disease in this population, a low threshold for 3-hydroxy-3-
methylglutaryl-coenzymeA (HMG-CoA) reductase inhi-
bitor therapy is indicated.
Aortic area
CMR is recognised as an accurate method for assessing
aortic dimensions and has been used to study the aorta in
both Marfan and Turner syndromes [46, 47]. In this study,
patients with GHD demonstrated significantly reduced
ascending AAi. This is a novel finding. Reduced aortic
diameter has been demonstrated in adults with CO-GHD,
which may reflect impaired development [48]. The only
study that looked at aortic diameter in patients with mainly
AO-GHD did not report any increase with GH replacement
but did not compare the aortic diameters of patients with
GHD to those of healthy individuals [8]. In our study, GH
replacement did not increase AA, confirming findings from
another study that failed to show an increase, even with 5
years of GH therapy [8]. The mechanisms behind the
reduction seen in AA in AO-GHD patients are not clear.
Reduced AA could be due to an impact of GH on blood
vessel development. Indeed, there are data to suggest that
IGF-1 is involved in angiogenesis and that children with
GHD have reduced retinal vascularisation [49]. However,
our patients had an average pre-diagnosis phase of 6.1
years, which does not seem long enough to have this impact
on AA. We cannot rule out that this might not be related to
endocrine abnormalities, although unlikely. An alternative
hypothesis for reduced AA is long-term reduced blood
pressure but our patient group did not have a significantly
different blood pressure compared to controls and there is
no convincing evidence that AO-GHD is associated with a
lower blood pressure.
Exclusions
Patients in whom a new, non-GH-related, cardiac diagnosis
was made were excluded from relevant analyses: patient 2
had LV hypertrophy thought to be due to hypertension and
diabetes and therefore was excluded from the cardiac mass
and indices analysis; patient 9 had a bicuspid aortic valve
and was excluded from AA analysis.
With patient 2 included within the calculations for this
study, the trend of reduced LVMi in GHD patients is lost
(53.9 ± 12.0 vs. 59.5± 8.0 g/m2, p= 0.232).There is, how-
ever, a significant increase in LVMi in GHD patients after
6 months of treatment (53.9 ± 12.0 vs. 56.6± 12.5 g/m2,
p= 0.0479) as well as 12 months of treatment when com-
pared to their initial LVMi (56.6± 11.8 vs. 59.5± 12.8 g/
m2, p= 0.0383). Over the 12 months, ANOVA calculations
showed a trend towards increasing LVMi in GHD patients
(56.6 ± 11.8 vs. 59.1± 12.4 vs. 59.5± 12.8 g/m2, ANOVA
p= 0.063). There remained no significant difference in all
other LV parameters when compared to baseline.
Limitations
We understand that this study was limited by small patient
numbers, a few exclusions and limited length of follow-up,
and future studies are needed to confirm these data.
Conclusions
We suggest that CMR could be used to identify and track
the cardiac changes that occur in patients with GHD. The
accurate assessment of LV mass by CMR allowed for the
demonstration of a trend towards reduced cardiac mass in
patients with AO-GHD and increase in cardiac mass with
GH replacement. RV-EDV was reduced in GHD and
reduced AAi was demonstrated in GHD patients.
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